TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00215657
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix 240 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
Study: NCT00215657
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix 240 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
Study: NCT00215657
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix 320 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
Study: NCT02775734
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate + Laparoscopic ovarian drilling
Study: NCT01517373
Drug: PF-04937319 100 mg
Normalized name: PF-04937319
DrugBank: PF-04937319 (DB15009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tablets and capsules, dose of 100 mg, a total of 3 pills/dose, administered once daily for 84-days
Study: NCT01517373
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination of tablets and capsules, dose of up to 6 mg, a total of 3 pills/dose, administered once daily for 84-days
Study: NCT00160875
Drug: Irinotecan hydrochloride trihydrate
Normalized name: Irinotecan hydrochloride trihydrate
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan (65mg/m2) weeks 1-2, 4-5, 7-8
Study: NCT00160875
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (30 mg/m2) weeks 1-2, 4-5, 7-8
Study: NCT01801644
Drug: gemcitabine plus cisplatin
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion followed by cisplatin 70 mg/m2 on day 1 as an 2 hour infusion
Study: NCT00401830
Drug: Lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet 400mg daily (200mg twice daily) during 8-week maintenance phase following 4-week titration phase starting at 100mg/day and increasing to 400mg/day at weekly intervals of 100mg
Study: NCT01885338
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03173430
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Blinatumomab (Blincyto), an anti-CD19/anti-CD3 bi-specific T cell engager
Study: NCT03177915
Drug: Hylase
Normalized name: Hylase Wound
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: median nerve hydro-dissection using Hyalase + 10 cc saline injection
Study: NCT03177915
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: median nerve hydro-dissection using 10 cc saline injection
Study: NCT04091438
Drug: TAK-925
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-925 IV infusion.
Study: NCT04365270
Drug: Chitosan Low Molecular Weight (20-200 Mpa.S)
Normalized name: chitosan low molecular weight (20-200 MPA.S)
DrugBank: Chitosan low molecular weight (20-200 mpa.s) (DB14155)
Approvals — FDA: no, EMA: no, PMDA: no
Description: deacetylated chitin, poly(D-glucosamine) purified by dissolving in 0.1 mol/L acetic acid, then precipitated in 0.1 mol/L sodium hydroxide and the precipitate will be washed with ethanol/water (70/30 v/v) mixture followed by freeze drying
Study: NCT04365270
Drug: Chlorhexidine Diacetate
Normalized name: Chlorhexidine diacetate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine antibacterial effect to be compared by Sigma-aldrich PHR 1222 , lot#LRAB3716
Study: NCT04365270
Drug: Titanium Dioxide
Normalized name: Titanium Dioxide
DrugBank: Titanium dioxide (DB09536)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titanium(IV) oxide,nanopowder, 21 nm primary particle size (TEM), \>99.5% trace metals basis cat#718467 Lot#MKCB6332 Lot #MKCB6332
Study: NCT02677922
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT02677922
Drug: AG-221
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT02601365
Drug: Sargramostim 0.04 mcg/kg/dose
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.04 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
Study: NCT02601365
Drug: Sargramostim 0.2mcg/kg/dose
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.2 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
Study: NCT02601365
Drug: Sargramostim 1 mcg/kg/dose
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 1 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
Study: NCT00951873
Drug: activated recombinant human factor VII, long acting
Normalized name: Activated Recombinant Human Factor VII, Long Acting
DrugBank: Eptacog alfa pegol (activated) (DB11661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of long acting activated recombinant human factor VII subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
Study: NCT00951873
Drug: activated recombinant human factor VII, long acting
Normalized name: Activated Recombinant Human Factor VII, Long Acting
DrugBank: Eptacog alfa pegol (activated) (DB11661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 0,1 mg/kg long acting activated recombinant human factor VII injected intravenously (into a vein).
Study: NCT01043029
Drug: aleglitazar
Normalized name: Aleglitazar
DrugBank: Aleglitazar (DB08915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aleglitazar 150 mcg po daily for 52 weeks
Study: NCT01043029
Drug: pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone 45 mg po daily for 52 weeks
Study: NCT03468465
Drug: Solifenacin Succinate
Normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg tablet daily during 75 days maximum
Study: NCT01179620
Drug: Certoparin
Normalized name: certoparin
DrugBank: Certoparin (DB09261)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certoparin
Study: NCT00089583
Drug: LEXIVA (GW433908)
Normalized name: Lexiva
DrugBank: Fosamprenavir (DB01319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosamprenavir suspension or tablet bid
Study: NCT00089583
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir solution bid
Study: NCT00098761
Drug: laromustine
Normalized name: Laromustine
DrugBank: Laromustine (DB05817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a dose escalation study. Participants receive 20, 30, 45, 60, 78, 103, 137, 182, or 242 mg/m2/day intravenously over 30 minutes for 5 consecutive days every 6 weeks up to 48 weeks.
Study: NCT00705276
Drug: Lactic acid (Dermacyd Femina Delicata)
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04197323
Drug: Alprostadil liposomes for injection
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40ug,once a day,continuous administration for 2 weeks
Study: NCT02656173
Drug: Mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT02656173
Drug: Tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT00656409
Drug: Conjugated pneumococcal vaccine (Prevenar)
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03549507
Drug: Sulfur hexafluoride lipid-type A microspheres
DrugBank: Sulfur hexafluoride (DB11104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg. Two bolus injections will be performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam.
Study: NCT03941093
Drug: Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
Normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: Pamrevlumab is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil.
Study: NCT03941093
Drug: Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Placebo is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil.
Study: NCT04110093
Drug: Regorafenib and PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All Colorectal cancer patients received regorafenib (80mg qd d1-d21,q4w) and PD-1 inhibitor. The patients could receive one type of PD-1 inhibitors according to oneself circumstance consideration including nivolumab (3mg/kg, ivgtt, q2w), Carelizumab (200mg, ivgtt, q3w), Sintilimab (200mg, ivgtt, q3w), Toripalimab(240mg ivgtt, q3w).
Study: NCT03566667
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betablocker
Study: NCT03681093
Drug: Fevipiprant 150 mg
Normalized name: Fevipiprant
DrugBank: Fevipiprant (DB12011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fevipiprant (QAW039) 150 mg once daily administered orally as tablet
Study: NCT03681093
Drug: Fevipiprant 450 mg
Normalized name: Fevipiprant
DrugBank: Fevipiprant (DB12011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fevipiprant (QAW039) 450 mg once daily administered orally as tablet
Study: NCT01821846
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered either alone or in combination therapy according to the package insert (PI). Self-administered once daily, at any time subcutaneously (s.c., under the skin) in the abdomen, thigh or upper arm).
Study: NCT00101738
Drug: Myfortic
Normalized name: Myfortic
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03777215
Drug: Angiotensin-(1-7)
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a biologically active beneficial hormone of the renin-angiotensin system.
Study: NCT03777215
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline will be used as the placebo comparator.
Study: NCT02267525
Drug: Velusetrag
Normalized name: Velusetrag
DrugBank: Velusetrag (DB12702)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00903344
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000IU vitamin D3 tablet taken daily
Study: NCT03146793
Drug: Sodium Thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25g intravenously 3 times per week
Study: NCT01501500
Drug: BOTOX
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: once injection of BTA 3oU into hallux oblique and transverse heads each
Study: NCT01501500
Drug: Normal Saline (0.9% NaCl)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.3ml to oblique and transverse heads each
Study: NCT03177798
Drug: Icatibant
Normalized name: Icatibant
DrugBank: Icatibant (DB06196)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, The investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
Study: NCT02172651
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take five 10,000 IU capsules (total 50,000 IU) once daily for 7 days, followed by one 10,000 IU capsule once daily until surgery.
Study: NCT04278924
Drug: TAK-079
Normalized name: Anti-Cd38 monoclonal antibody TAK-079
DrugBank: Mezagitamab (DB16370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-079 SC injection.
Study: NCT03707340
Drug: Flibanserin Pill
Normalized name: flibanserin Pill
DrugBank: Flibanserin (DB04908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible participants will begin treatment with flibanserin 100 mg orally daily at bedtime for 24-36 weeks and followed for a total of 52 weeks.
Study: NCT01725282
Drug: quetiapine extended release (XR)
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended release tablets
Study: NCT04544111
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2mg by mouth daily~\*If patient loses the ability to swallow while on study, trametinib may be provided as a powder in bottle for reconsititution. Trametinib, as a powder in bottle, will be mixed with sterile/purified water into an oral solution and administered PO or through enteral feeding tube
Study: NCT04544111
Drug: Dabrafenib
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150 mg twice daily (OR at dose the patient previously tolerated)
Study: NCT04581629
Drug: Encaleret
Normalized name: Encaleret
DrugBank: Encaleret (DB18096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT04652882
Drug: Tasimelteon
Normalized name: Tasimelteon
DrugBank: Tasimelteon (DB09071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral capsule
Study: NCT03515304
Drug: Evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 420 mg evolocumab administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
Study: NCT00384150
Drug: galiximab in combination with rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: galiximab (500 mg/m2 IV) in combination with rituximab (375 mg/m2 IV)once weekly for 4 weeks.
Study: NCT03004495
Drug: CHF5259 and CHF6001
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: b.i.d. for 14 days
Study: NCT01409200
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02372357
Drug: Posaconazole prophylaxis 120 mg/m² tid
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients are receiving posaconazole to prevent invasive fungal infections in a dose of 120 mg/m² tid
Study: NCT02349477
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gaba potentiating medication
Study: NCT02257021
Drug: BILR 355 BS
Normalized name: BS-001
DrugBank: BS-001 (DB17415)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02257021
Drug: Tipranavir
Normalized name: Tipranavir
DrugBank: Tipranavir (DB00932)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02257021
Drug: Low dose of ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02257021
Drug: High dose of ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00406731
Drug: NG-monomethyl-L-arginine (L-NMMA)
Normalized name: NG-Monomethyl-L-arginine
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bolus 6 mg/kg over 5 minutes followed by a continuous intravenous infusion of 60 µg/kg/min over 12 minutes; twice on 1 study day
Study: NCT00406731
Drug: Endothelin-1 (ET-1)
Normalized name: nitric oxide synthase endothelial
DrugBank: Endothelin-1 (DB12652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ng/kg/min intravenous infusion over 17 minutes; twice on 1 study day
Study: NCT01082458
Drug: remifentanil / lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil TCI group : target controlled infusion of 2.0ng/ml of remifentanil on end of surgery.~Lidocaine IV group : Intravenous administration of 1.5mg/kg of lidocaine on end of surgery.
Study: NCT01674361
Drug: Bitopertin
Normalized name: Bitopertin
DrugBank: Bitopertin (DB12426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitopertin once daily orally.
Study: NCT01674361
Drug: SSRI
Normalized name: SSRI - Selective serotonin re-uptake inhibitor
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will continue their background SSRI treatment as per standard of care at the same dose taken during the 8 weeks prior to Day 1. Protocol does not enforce any particular SSRI drug or regimen.
Study: NCT00754559
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8mg/kg iv every 4 weeks
Study: NCT01248468
Drug: Sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg Sumatriptan
Study: NCT00801255
Drug: danoprevir
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg po bid/100mg po q8h for 14 days
Study: NCT00801255
Drug: danoprevir
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg po bid/100mg po q8h for 14 days\\n500mg po bid/200mg po q8h for 14 days
Study: NCT00801255
Drug: danoprevir
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg po bid/200mg po q8h for 14 days
Study: NCT00801255
Drug: danoprevir
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg/600mg po twice daily for 14 days
Study: NCT00801255
Drug: danoprevir
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg/900mg po twice daily for 14 days
Study: NCT03813121
Drug: midazolam intravenous infusion
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive a single drug infusion
Study: NCT03813121
Drug: ketamine intravenous infusion
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a single drug infusion
Study: NCT02100644
Drug: Lamotrigine tablets 25/100 mg
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) is administered according to the package insert: that is, 25 mg of LTG will be orally administered once every other day for the first 2 weeks and then once daily for the next 2 weeks. Thereafter, the dose will be gradually escalated by 25-50 mg every 1-2 week for once or twice daily administration. During the VPA reduction phase and LTG\&amp;VPA maintenance phase, as specified in the information of package insert, maintenance dose of LTG will be administered twice daily.
Study: NCT00274950
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00274950
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00274950
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00274950
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00274950
Drug: vinblastine sulfate
Normalized name: Vinblastine Sulfate
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00833729
Drug: etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50 mg twice weekly (BIW) for 12 wks followed by a dose reduction to 50mg once weekly (OW) for an additional 12 weeks.
Study: NCT00389480
Drug: AR-67 (formerly DB-67)
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion daily x 5 days, every 21 days